HHS Secretary Azar Returns to Senate for Hearing on Drug PricingImage Banner

HHS Secretary Azar Returns to Senate for Hearing on Drug Pricing

You are here

HHS Secretary Azar Returns to Senate for Hearing on Drug Pricing

July 2, 2018

According to the American Journal of Managed Care:

HHS Secretary Alex Azar appeared before the Senate Committee on Finance today to discuss the Trump administration’s efforts to drive drug innovation and affordability, answering a slew of questions revolving around the “American Patients First” blueprint, increasing generic and biosimilar competition, and value-based pricing.

[…]

As he mentioned last week when appearing before the Senate Committee on Health, Education, Labor, and Pensions, Azar pointed out 4 significant problems the healthcare system faces: high list prices set by manufacturers, seniors and government programs overpaying for drugs due to a lack of negotiation tools, rising out-of-pocket costs, and foreign government ‘free riding.’”

ANCOR generally follows the Secretary’s visits to Congress given his importance to I/DD programs. ANCOR members interested in learning more about this hearing in particular can find notes prepared by our lobbyists here.